-

GeNeuro SA: End of the Liquidity Contract With GILBERT DUPONT

GENEVA--(BUSINESS WIRE)--Regulatory News:

GeNeuro SA (Paris:GNRO) and GILBERT DUPONT have terminated the liquidity contract entered into on March 6, 2021.

This termination took effect on June 30, 2024, after market closing.

On that date of 30 June 2024 post market closing, the following assets appeared on the liquidity contract:

  • Number of shares: 93,539
  • Cash balance of the liquidity account: € 91,665.80

As a reminder, as of 29 December 2023, the following resources were booked to the liquidity account:

  • Number of shares: 118,739
  • Cash balance of the liquidity account: € 48,977.59

It is also reminded that at the initial implementation of the contract, the following resources were included in the liquidity account:

  • Number of shares: nil
  • Cash: € 750,000.00

Following the closure of the liquidity contract, the securities and cash were transferred to the Company.

For more information, please visit the website : www.geneuro.com

Contacts

GeNeuro

Jesús Martin-Garcia

Président et directeur général
+41 22 552 4800
investors@geneuro.com

NewCap (France)

Louis-Victor Delouvrier (investors)

+33 1 44 71 98 52
Arthur Rouillé (médias)
+33 1 44 71 94 98
geneuro@newcap.eu

GeNeuro SA

BOURSE:GNRO
Release Versions
EnglishFrench

Contacts

GeNeuro

Jesús Martin-Garcia

Président et directeur général
+41 22 552 4800
investors@geneuro.com

NewCap (France)

Louis-Victor Delouvrier (investors)

+33 1 44 71 98 52
Arthur Rouillé (médias)
+33 1 44 71 94 98
geneuro@newcap.eu

More News From GeNeuro SA

GeNeuro SA Postpones Publication of June 30, 2025 Half-Yearly Financial Report

GENEVA--(BUSINESS WIRE)--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces the postponement of its June 30, 2025 half-yearly results and half-yearly financial report. This decision is in line with the postponement of the annual results for the fiscal year ended December 31, 2024, annual results and annual financial report in order to be able to take into account the finan...

GeNeuro SA Announces the Extension of its Definitive Debt-Restructuring Moratorium

GENEVA--(BUSINESS WIRE)--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Geneva Court of First Instance has, in a September 25, 2025, judgment, granted GeNeuro SA an extension of its definitive debt-restructuring moratorium until January 27, 2026, under the continued supervision of the court-appointed commissary. Definitive Debt-Restructuring Moratorium As prev...

GeNeuro SA Announces the Liquidation of Its French Subsidiary GeNeuro Innovation SAS

GENEVA--(BUSINESS WIRE)--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Lyon Economic Activities Court has pronounced on July 15, 2025, the liquidation of GeNeuro Innovation SAS, the sole subsidiary of GeNeuro SA. This decision follows the opening on June 11, 2025, of receivership proceedings for GeNeuro Innovation SAS. The Court appointed SELARL MJ-Synergie a...
Back to Newsroom